What top creators are saying about Hims & Hers Health, Inc.(HIMS)— Page 7

The stock is facing significant uncertainty due to a public dispute with Novo Nordisk. Investors are divided, with the host remaining long while a guest presented a bearish case based on legal and reputational risk.

The speaker is very bullish, calling it the 'clear winner' and 'very cheap' given its high growth rate, diversified business model, and superior marketing, believing the market misjudges it by focusing only on GLP-1 risks.

The CEO's dispute with Novo Nordisk is viewed as a tough 'David vs. Goliath' battle that creates uncertainty for the stock.

Stock was hit very hard, down 35%, after losing a partnership. The news is viewed by investors as a 'thesis breaker' due to concerns about its ability to compete with Big Pharma.

Despite the stock falling 35% after losing its Novo Nordisk partnership, the speaker is not selling and believes the market overreacted, presenting 'buy the dip' or selling puts as attractive bullish strategies.

The speaker advises caution, noting the stock's 34% drop due to a dispute with Novo Nordisk and questions the scalability and margin potential of its business model, which he views as a low-margin pharmacy/distributor.

The stock plummeted over 35% after terminating its partnership with Novo Nordisk. Investors are divided, with some seeing it as a 'thesis breaker' due to a lack of competitive moat, while others view it as a 'massive overreaction.' Short interest is at an all-time high.

The significant stock drop following the Novo Nordisk partnership termination is viewed as a buying opportunity and an overreaction, as the affected GLP-1 business is only 15-20% of revenue. The long-term bullish thesis is based on its model of disrupting primary care.

Novo Nordisk terminated its partnership with the company, and Bank of America reiterated a sell rating with a $28 price target, citing concerns of decelerating revenue growth.